SMH
AVDL

Sanders Morris Harris’s Avadel Pharmaceuticals AVDL Stock Holding History

Sanders Morris Harris’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-15,000
Closed -$166K – 247
2016
Q1 		$166K Buy
+15,000
New +$149K 0.03% 289

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
FPC
Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Sanders Morris Harris's AVDL Position: Q2 2016 in Review

Sanders Morris Harris sold out of Avadel Pharmaceuticals (AVDL) in Q2 2016, closing a stake of 15,000 shares — an estimated $166K sold.

Sanders Morris Harris first reported a position in AVDL in Q1 2016 and held it in 1 quarter. The position peaked at $166K in Q1 2016. 84 funds tracked by Wall St. Rank hold AVDL as of Q2 2016.

  • Sanders Morris Harris reported no remaining Avadel Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Sanders Morris Harris sold 15,000 Avadel Pharmaceuticals shares in Q2 2016, an estimated $166K.
  • Sanders Morris Harris first reported a position in Avadel Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Sanders Morris Harris's Avadel Pharmaceuticals position peaked at $166K in Q1 2016.
  • 84 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2016.

Based on Sanders Morris Harris's 13F filing for Q2 2016, filed 25 Jul 2016.